Form 4: Spyre Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., sold 25,000 shares of common stock on September 30, 2026.
Summary
- Option exercise/conversion: acquired 17,500 Common Stock at $14.50 ($253,750) on September 30, 2026; holds 97,262 after (Direct).
- Open-market sale: disposed of 17,500 Common Stock at $89.89 ($1,573,075) on September 30, 2026; holds 79,762 after (Direct).
- Option exercise/conversion: acquired 7,500 Common Stock at $14.50 ($108,750) on October 1, 2026; holds 87,262 after (Direct).
- Open-market sale: disposed of 600 Common Stock at $89.07 ($53,442) on October 1, 2026; holds 86,662 after (Direct).
- Open-market sale: disposed of 1,500 Common Stock at $90.27 ($135,405) on October 1, 2026; holds 85,162 after (Direct).
- Open-market sale: disposed of 2,100 Common Stock at $91.92 ($193,032) on October 1, 2026; holds 83,062 after (Direct).
- Open-market sale: disposed of 3,071 Common Stock at $92.95 ($285,449) on October 1, 2026; holds 79,991 after (Direct).
- Open-market sale: disposed of 229 Common Stock at $93.57 ($21,428) on October 1, 2026; holds 79,762 after (Direct).
- Option exercise/conversion: disposed of 17,500 Stock Option (Right to Buy) on September 30, 2026; holds 319,857 after (Direct).
- Option exercise/conversion: disposed of 7,500 Stock Option (Right to Buy) on October 1, 2026; holds 312,357 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,261,831 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Scott L Burrows — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Common Stock | 17,500 | $15 | $253.8K | 97,262 |
| 2026-09-30 | Open-market sale | Common Stock | 17,500 | $90 | $1.6M | 79,762 |
| 2026-10-01 | Option exercise/conversion | Common Stock | 7,500 | $15 | $108.8K | 87,262 |
| 2026-10-01 | Open-market sale | Common Stock | 600 | $89 | $53.4K | 86,662 |
| 2026-10-01 | Open-market sale | Common Stock | 1,500 | $90 | $135.4K | 85,162 |
| 2026-10-01 | Open-market sale | Common Stock | 2,100 | $92 | $193.0K | 83,062 |
| 2026-10-01 | Open-market sale | Common Stock | 3,071 | $93 | $285.4K | 79,991 |
| 2026-10-01 | Open-market sale | Common Stock | 229 | $94 | $21.4K | 79,762 |
| 2026-09-30 | Option exercise/conversion | Stock Option (Right to Buy) | 17,500 | — | — | 319,857 |
| 2026-10-01 | Option exercise/conversion | Stock Option (Right to Buy) | 7,500 | — | — | 312,357 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (17,500 shares) |
| 2026-09-30 | Open-market sale (17,500 shares) |
| 2026-10-01 | Option exercise/conversion (7,500 shares) |
| 2026-10-01 | Open-market sale (600 shares) |
| 2026-10-01 | Open-market sale (1,500 shares) |
| 2026-10-01 | Open-market sale (2,100 shares) |
| 2026-10-01 | Open-market sale (3,071 shares) |
| 2026-10-01 | Open-market sale (229 shares) |
| 2026-09-30 | Option exercise/conversion (17,500 shares) |
| 2026-10-01 | Option exercise/conversion (7,500 shares) |
Keywords
insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Scott L Burrows
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.